Tnf-alpha antagonism in severe asthma?

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 4, Issue 3, 2010, Pages 193-200

  Desai, Dhananjay ^a   Brightling, Christopher ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Airway smooth muscle; Asthma; Mast cells; Refractory asthma; Tnf

Indexed keywords

ETANERCEPT; GOLIMUMAB; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; PLACEBO; RTNV 148B; SIMPONI; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADD ON THERAPY; AIRWAY; AIRWAY HYPERRESPONSIVENESS; AIRWAY REMODELING; AIRWAY SMOOTH MUSCLE; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CANCER RISK; CELL MIGRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; ENTERITIS; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HEMIPLEGIA; HUMAN; INFECTION; INFECTION RISK; INFLAMMATORY CELL; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; LUNG FUNCTION; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; MELANOMA; MONOCYTE; NEUTROPHIL; NONHUMAN; PATENT; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR AFFINITY; RHEUMATOID ARTHRITIS; SEPSIS; SMOOTH MUSCLE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 78649344217     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221310793564218     Document Type: Article

References (98)

1. Bousquet J, Bousquet PJ, Godard P, Daures JP. The public health implications of asthma. Bull World Health Organ 2005; 83(7): 548-54.
2. Braman SS. The global burden of asthma. Chest 2006; 130: 4S-12S.
3. Global Initiative for Asthma Guidelines 11/06. Available from: http: //www.ginasthma.com [Accessed on: Feb 2010]
4. British Thoracic Society Asthma Guidelines 06/09. Available from http: //www.brit-thoracic.org.uk [Accessed on: Feb 2010]
5. American Thoracic Society. Proceedings of the ATS Workshop on Refractory Asthma: Current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2001; 62(6): 2341-51.
6. Moore WC, Peters SP. Severe asthma: An overview. J Allergy Clin Immunol 2006; 117(3): 487-94.
7. Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet LP, et al. Severe asthma in adults: What are the important questions? J Allergy Clin Immunol 2007; 119(6): 1337-48.
8. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, et al. Tumour necrosis factor (TNF alpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60(12): 1012-8.
9. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354(7): 697-708.
10. Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. Curr Opin Allergy Clin Immunol 2007; 7(1): 43-50.
11. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178(3): 218-24.
12. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010; 181(4): 315-23.
13. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295(19): 2275-85.
14. Medzhitov R, Janeway C. Innate immunity. N Engl J Med 2000; 343(5): 338-44.
15. Glauser M, Zanetti G, Baumgartner JD. Septic shock: Pathogenesis. Lancet 1991; 338: 732-6.
16. Thomas PS. Tumor necrosis factor: The Role of this multi- functional cytokine in asthma. Immunol Cell Biol 2001; 79: 132-40.
17. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 1988; 53(1): 45-53.
18. Zheng Y, Saftig P, Hartmann D, Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNF) shedding and of the function of the TNF alpha ectodomain in ensuring selective stimulated shedding by the TNF alpha convertase (TACE/ADAM17). J Biol Chem 2004; 279(41): 42898-906.
19. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. Biol Chem 1987; 262(15): 6951-4.
20. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990; 87(8): 3127-31.
21. Liu ZG. Molecular mechanism of TNF signalling and beyond. Cell Res 2005; 15(1): 24-7.
22. Mukaida N, Mahe Y, Matsushima K. Cooperative interaction of nuclear factor-kappa B- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem 1990; 265(34): 21128-33.
23. Kim EY, Priatel JJ, Teh SJ, Teh HS. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 2006; 176(2): 1026-35.
24. Kim EY, Teh HS. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol 2001; 167(12): 6812-20.
25. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344(12): 907-16.
26. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350(21): 2167-79.
27. Ying S, Robinson DS, Varney V, Meng Q, Tsicopoulos A, Moqbel R, et al. TNF alpha mRNA expression in allergic inflammation. Clin Exp Allergy 1991; 21(6): 745-50.
28. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4,-5, and -6 and tumor necrosis factor- alpha in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10(5): 471-80.
29. Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 1995; 152(1): 76-80.
30. Huber M, Beutler B, Keppler D. Tumor necrosis factor alpha stimulates leukotriene production in vivo. Eur J Immunol 1988; 18(12): 2085-8.
31. Thomas PS, Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 2002; 57(9): 774-8.
32. Lukacs NW, Strieter RM, Chensue SW, Widmer M, Kunkel SL. TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol 1995; 154(10): 5411-7.
33. Slungaard A, Vercellotti GM Slungaard A, Vercellotti GM, Walker G. Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med 1990; 171(6): 2025-41.
34. Scheurich P, Thoma B, Ucer U, Pfizenmaier KP. Immuno- regulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: Induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 1987; 138(6): 1786-90.
35. Lassalle P, Delneste Y, Gosset P, Tonnel AB, Capron AP. Potential implication of endothelial cells in bronchial asthma. Int Arch Allergy Appl Immunol 1991; 94(1-4): 233-8.
36. Walter MJ, Morton JD, Kajiwara N, Agapov E, Holtzman MJ. Viral induction of a chronic asthma phenotype and genetic segregation from the acute response. J Clin Invest 2002; 110(2): 165-75.
37. Amrani Y, Panettieri RA Jr, Frossard N, Bronner C. Activation of the TNF alpha-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells. Am J Respir Cell Mol Biol 1996; 15(1): 55-63.
38. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122(1): 103-11.
39. Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal regulated kinase pathway. Am J Respir Cell Mol Biol 2005; 32(4): 342-9.
40. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, Chrousos GP, et al. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: Potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999; 84(8): 2834-9.
41. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346(22): 1699.
42. Berger P, Girodet PO, Begueret H, Ousova O, Perng DW, Marthan R, et al. Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. FASEB J 2003; 17(14): 2139-41.
43. Brightling CE. Chronic cough due to non asthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006; 129(1 Suppl): 116S-21S.
44. Amin K, Janson C, Boman G, Venge P. The extracellular deposition of mast cell products is increased in hypertrophic airways smooth muscles in allergic asthma but not in nonallergic asthma. Allergy 2005; 60(10): 1241-7.
45. Slats AM, Janssen K, van Schadewijk A, van der Plas DT, Schot R, van den Aardweg JG, et al. Bronchial Inflammation and Airway Responses to Deep Inspiration in Asthma and COPD. Am J Respir Crit Care Med 2007; 176(2): 121-8.
46. Brightling CE, Symon FA, Birring SS, Bradding P, Wardlaw AJ, Pavord ID. Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax 2003; 58(6): 528-32.
47. Brightling CE, Ward R, Goh KL, Wardlaw AJ, Pavord ID. Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 1999; 160(2): 406-10.
48. Brightling CE. Chronic cough due to nonasthmatic eosinophilic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 116S-21S.
49. Chen FH, Samson KT, Miura K, Ueno K, Odajima Y, Shougo T, et al. Airway remodeling: A comparison between fatal and nonfatal asthma. J Asthma 2004; 41(6): 631-8.
50. Carroll NG, Mutavdzic S, James AL. Distribution and degranu- lation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002; 19(5): 879-85.
51. Gordon J, Galli S. Mast cells as a source of both preformed and immunologically inducible TNF- /cachectin. Nature 1990; 346(6281): 274-6.
52. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor-, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991; 88: 4220-4.
53. Reuter S, Heinz A, Sieren M, Wiewrodt R, Gelfand EW, Stassen M, et al. Mast cell-derived tumour necrosis factor is essential for allergic airway disease. Eur Respir J 2008; 31(4): 773-82.
54. van Houwelingen AH, Kool M, de Jager SC, Redegeld FA, van Heuven-Nolsen D, Kraneveld AD, et al. Mast cell-derived TNF- alpha primes sensory nerve endings in a pulmonary hypersensitivity reaction. J Immunol 2002 5; 168(10): 5297-302.
55. Nakae S, Ho LH, Yu M, Monteforte R, Iikura M, Suto H, et al. Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. J Allergy Clin Immunol 2007; 120(1): 48-55.
56. Puxeddu I, Ribatti D, Crivellato E, Levi-Schaffer F. Mast cells and eosinophils: A novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol 2005; 116(3): 531-6.
57. Sukkar MB, Hughes JM, Armour CL, Johnson PR. Tumor necrosis factor-alpha potentiates contraction of human bronchus in vitro. Respirology 2001; 6(3): 199-203.
58. Anticevich SZ, Hughes JM, Black JL, Armour CL. Induction of human airway hyperresponsiveness by tumour necrosis factoralpha. Eur J Pharmacol 1995; 284(1-2): 221-5.
59. Moeller, A., Emling, F. Monoclonal antibodies against human tumor necrosis factor TNF, and use thereof. US5231024 (1993).
60. Barbanti, E., Ghislieri, M., Marcucci, F., Trizio, D. Monoclonal antibodies against human tumor necrosis factor. US5436154 (1995).
61. Boyle, P., Wetzel, G.D., Lembach, K.J. Human anti-TNF antibodies. US5654407 (1997).
62. Le, J., Vilcek, J., Daddona, P., Ghrayeb, J., Knight, D., Siegel, S. Human anti TNF antibodies and peptides. US20080033149 (2008).
63. Newman, R.A., Hanna, N., Raab, R.W. Recombinant antibodies for human therapy. US5750105 (1998).
64. Le, J., Vilcek, J., Dadonna, P., Ghrayeb, J., Knight, D., Seigal, S. Methods of treating TNFα-mediated disease using chimeric anti- TNF antibodies. US5919452 (1999).
65. Rathjen, D. A., Aston, R. Tumour necrosis factor binding ligands. US5959087 (1999).
66. Rathjen, D.A., Aston, R. Tumor necrosis factor binding ligands.US20100125130 (2010).
67. Smith, C. A., Goodwin, R. G., Beckmann, P. M. Purified p75 (type II) tumor necrosis factor receptor polypeptides (Etanercept). US5945397 (1999).
68. Le, J., Vilcek, J., Daddona, P., Ghrayeb, J., Knight, D., Siegel, S. Anti TNF antibodies for diagnosis of TNF mediated conditions. US6277969 (2001).
69. Le, J., Vilcek, J., Daddona, P., Ghrayeb, J., Knight, D., Siegel, S. Anti TNF antibodies and peptides of human necrosis factor. US6790444 (2004).
70. Knight, D. M., Shealy, D. J. Anti-TNF antibodies and peptides of human tumor necrosis factor. US20060246073 (2006).
71. Le, J., Vilcek, J., Daddona, P., Ghrayeb, J., Knight, D., Siegel, S. Anti TNF antibodies and peptides of human necrosis factor. US6991791 (2006).
72. Le, J., Vilcek, J. T., Daddona, P. E., Ghrayeb, J., Knight, D. M., Siegel, S.A., Shealy, D. J. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptiedes of human tumor necrosis factor. US20090041762 (2009).
73. Meade, C. J. M., Pieper, M. P., Pairet, M. New pharmaceutical compositions based on anticholinergics and anti-TNF antibodies. US20060251656 (2006).
74. Li, L.-C., Shi, Y., Reiland, T.L., Sakagami, M., Nicholson, K., Byron, P. R. Methods and compositions for pulmonary administration of a TNFa inhibitor. US20090110679 (2009).
75. Hellendoorn, K., Baker, M.,Carr, F.J. Modified anti TNF antibody (Infliximab). US7524502 (2009).
76. Bossard, M.J., Stephenson, G. Conjugates of an anti-tnf alpha antibody. United States Patent Application US20100021481 (2010).
77. Rubin, B. Y., Anderson, S. L., Sullivan, S. A., Old, L. J., Williamson, B. D., Richards, E. C., Rubin, B. Y., Anderson, S.L. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor. EP0218868 (1985).
78. Moeller, A., Emling, F. Monoclonal antibodies against human tumour necrotic factor TNF, and their use. EP0260610 (1988).
79. Rathjen, D. A., Aston, R. Tumor necrosis factor binding ligands. US20030170204 (2003).
80. Wallach, D., Brakebusch, C. Multimers of the soluble forms of TNF receptors, their preparation and pharmaceutical compositions containing them. EP0526905 (2004).
81. Boyle, P., Wetzel, G.D. Human anti TNF antibodies. EP0614984 (1994).
82. Wallach, D., Engelmann, H. Antibodies to TNF binding protein I and F (ab) fragments thereof. EP0412486 (1994).
83. Rathjen, D.A., Aston, R. Tumor necrosis factor binding ligands. WO002078 (1991).
84. Greene, M. I., Murali, R., Cheng, X., Ottenbrite, R., Xiao, Y. Tumor necrosis factor inhibitors. US20090221527 (2009).
85. Banerjee, S., Taylor, L. K. Treatment of pulmonary disorders using TNF alpha inhibitor. US2004131614 (2004).
86. Khalil SC, Brown DM, Chumney-Malacar J, Crow J. Infliximab therapy for rheumatoid arthritis (RA) induced significant control of asthma in patients with both RA and asthma or asthma/COPD. J Allergy Clinl Immunol 2002; 109(1): S243.
87. Rouhani FN, Meitin CA, Kaler M, Miskinis-Hilligoss D, Stylianou M, Levine SJ. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 2005; 99(9): 1175-82.
88. Jacobs, C.A., Smith, C. A. Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor. US05605690 (1997).
89. Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006; 174(7): 753-62.
90. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNF receptor fusion protein (Etanercept) in corticosteroid refractory asthma: A double blind, randomised, placebo controlled trial. Thorax 2008; 63(7): 584-91.
91. Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Nelson H, et al. A randomized double-blind, placebo controlled trial evaluating the safety and efficacy of etanercept 25 twice weekly in patients with severe persistent asthma. Chest 2007; 132(4): 436S.
92. Wenzel S, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, et al. A Randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179(7): 549-58.
93. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(9): 926-34.
94. Leombruno JP, Einarson TR, Keystone EC. The safety of antitumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68(7): 1136-45.
95. Joint Tuberculosis Committee of the British Thoracic Society. Recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF- treatment. Thorax 2005; 60; 800-5.
96. Cox LS. How safe are the biologicals in treating asthma and rhinitis? Ann Rheum Dis 2009; 68(7): 1136-45.
97. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNF alpha blockade in human diseases: Mechanisms and future directions. Clin Immunol 2008; 126(2): 121-36.
98. Siddiqui S, Brightling CE. Magic bullets: The new goal for asthma. Am J Respir Crit Care Med 2009; 180: 383-4.